Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Switzerland joins embryonic stem cell R&D (research and development) race:

This article was originally published in Clinica

Executive Summary

The Swiss population has overwhelmingly approved of new legislation permitting embryonic stem cell research, through a referendum that had been called with the aim of repealing, on ethical grounds, a law passed by the government in December 2003. Two-thirds (1,156,613 or 66.4%) of the votes cast backed the new law, while 33.6% (585,414 votes) went against. The approved law allows the use only of embryos left over from in vitro fertilisation. The government welcomed the result of the referendum, citing its importance for the major bioscience companies based in Switzerland, for the progress of medicine, especially with regard to potentially finding cures for conditions such as paraplegia, diabetes, myocardial infarction and Alzheimer's disease. The new law comes into force in March 2005.

You may also be interested in...

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

US Medicare Agency Alters Payments For Use Of Telehealth Tech, Lab Specimen Collection For COVID-19

An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts